Thomas Daniels
Quantum BioPharma Ltd., a Canadian biopharmaceutical firm listed on NASDAQ, has expanded its cryptocurrency portfolio with an additional $1 million investment in Bitcoin and other digital assets. This latest acquisition raises the company’s total crypto holdings to approximately $4.5 million.
According to a May 19 announcement, Quantum’s board-approved strategy includes staking a portion of its digital assets to generate revenue, marking a move to actively utilize its crypto treasury rather than merely holding it. The company views its Bitcoin and broader cryptocurrency investments as a hedge against depreciation of the Canadian dollar and as a means to deliver shareholder returns.
Following the disclosure, Quantum’s stock (QNTM) surged by approximately 25%, reflecting investor optimism around its alternative treasury strategy.
Quantum BioPharma joins a growing cohort of healthcare firms adopting Bitcoin as a treasury asset. In March, Atai Life Sciences, a NASDAQ-listed biotech firm, announced plans to allocate $5 million toward Bitcoin. Atai’s founder, Christian Angermayer, has publicly advocated for Bitcoin as a critical element of corporate treasuries, particularly in capital-intensive industries like biotechnology where long R&D cycles require robust fiscal buffers.
Similarly, Basel Medical Group, headquartered in Singapore, revealed plans last week to acquire $1 billion in Bitcoin. The company stated this move would enhance its financial foundation as it pursues expansion across Asia. However, unlike Quantum, Basel’s shares fell sharply post-announcement, underscoring the volatility in market reception to such strategies.
The trend is part of a broader shift in corporate finance. As of May 2025, corporate treasuries collectively hold over $83 billion in Bitcoin, with publicly traded firms emerging as the second-largest institutional holders behind ETFs.
Fidelity Digital Assets emphasized in a 2024 report that Bitcoin may serve as a hedge against fiscal imbalances, currency devaluation, and geopolitical uncertainty—a thesis increasingly tested in corporate boardrooms.
